AlphAIalphai — Financial news for AI agents
stockinvest.usAUG 202 min read$RYTM

TD Cowen Names Rhythm Pharmaceuticals Its Top Pick Following Robust Q2 Results

Rhythm Pharmaceuticals (RYTM) was named TD Cowen's top pick after strong Q2 results. Imcivree revenue hit $71.3M, up 19% QoQ and 50% YoY, driven by U.S. sales growth. Clinical data for RM-718 showed a 11.6% BMI reduction. TD Cowen maintained a buy rating with a $130 price target, citing commercial and clinical progress.

Original reporting
stockinvest.us
Published Aug 20, 2026, 6:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 8:15 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$RYTM
Bullish
high confidence
Mentioned
$RYTM
Relevance
7/10
alphai data visualization · based on stockinvest.us
Decision brief

The 30-second read

$RYTMBullishMed
01

Why it matters

Earnings beat and analyst upgrade provide a fresh catalyst for price movement.

02

Market read

The Q2 beat and upgrade are likely to attract short‑term buying interest in RYTM.

03

What to watch

Potential regulatory or payer hurdles for upcoming Prader‑Willi trial could delay revenue upside.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Rhythm Pharmaceuticals (RYTM) is a Nasdaq‑listed biotech focused on rare obesity disorders.

Company-level read

Ticker impact

$RYTMBullishHigh confidence
Context

Rhythm Pharmaceuticals reported Q2 revenue of $71.3M beating estimates and received a TD Cowen buy rating with a $130 price target.

Expected impact

Potential upside of 5-10% as investors price in higher guidance.

Evidence & confidence

Revenue beat and new buy rating are fresh, material information for a small‑cap biotech.

Market effects

Sector

Strengthens the rare‑disease obesity biotech sector, supporting peers with MC4R programs.

Regional

U.S. biotech stocks may see modest gains; European exposure muted by revenue dip.

Global

Highlights growing demand for obesity therapies worldwide.

Counterpoint

What could challenge this read

European revenue decline and reimbursement challenges could pressure the stock despite U.S. beat.

Key entities

  • analyst
    TD Cowen

    Provided buy rating and $130 price target.

  • product
    Imcivree

    Flagship drug driving revenue growth.

Read at source← All news

Related articles

AUG 24
$RYTMHighAI 8/10

Rhythm Wins Japan Nod For IMCIVREE As First Treatment For Acquired Hypothalamic Obesity; Stock Up

Rhythm Pharmaceuticals (RYTM) received Japanese approval for IMCIVREE to treat acquired hypothalamic obesity, a rare condition. The approval follows a Phase 3 trial showing significant BMI reduction. Rhythm estimates 5,000-8,000 people in Japan have this condition. The UK also expanded IMCIVREE's authorization. RYTM stock is up 0.99% to $110 at close, down 0.72% in pre-market.

rttnews.com2 min
AUG 11
$RYTMMedAI 8/10

Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript

Rhythm Pharmaceuticals (RYTM) reported Q2 2026 revenue of $71.3M, up 19% sequentially. U.S. revenue was $51M, up 38% sequentially, while international sales fell to $20.3M due to a $3.8M French retrospective charge. Management said cash and short-term investments were $330.9M, guiding FY26 non-GAAP OpEx to $363M-$397M and R&D to $175M-$195M.

fool.com6 min
AUG 5
$RYTMMed

Rhythm Pharmaceuticals reports RM-718 trial results in obesity

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported preliminary Phase 2 results for RM-718, a once-weekly MC4R agonist, in acquired hypothalamic obesity. In 7 patients completing 16 weeks, mean BMI fell 11.6% from baseline. The company cited comparisons versus bivamelagon (10.1% at 14 weeks) and setmelanotide (10.1% at 16 weeks). Mild injection-site hyperpigmentation and common GI side effects were reported.

investing.com4 min
AUG 4
$RYTMMed

Rhythm Pharmaceuticals Reports Positive Signal For RM-718 In Rare Obesity Disorder

Rhythm Pharmaceuticals (RYTM) reported preliminary Phase 2 results for RM-718, an investigational once-weekly MC4R agonist for acquired hypothalamic obesity. In 11 enrolled patients, 7 reached 16 weeks. Interim data showed mean BMI down 11.6% from baseline, with two mild injection-site hyperpigmentation cases and generally tolerable side effects. Two discontinued; eight remained on treatment as of mid-July 2026.

rttnews.com4 min
AUG 4
$RYTMMed

Rhythm Pharmaceuticals Q2 Earnings Call Highlights

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Q2 U.S. product revenue of $51M (72% of product sales) and said growth was driven by acquired HO and Bardet-Biedl syndrome demand. International revenue fell to $20.3M due to a France Contribution M charge. GAAP net loss was $0.73/share; cash was ~$331M. RM-718 Phase II Part C showed 11.6% mean BMI reduction at week 16 in 7 patients.

yahoo.com7 min